Powered by

Stallergenes' allergy immunotherapy hits goal in phase 3

Nov 20, 2018 - FierceBiotech

A phase 3 trial of Stallergenes Greer's treatment for house dust mite (HDM)-induced allergic rhinitis has met its primary endpoint. The late-phase success sets Stallergenes up to file for FDA approval of oral immunotherapy STAGR320.

Investigators enrolled 1,600 patients in the clinical trial and randomized them to receive daily doses of STAGR320 or placebo for 12 months. Stallergenes hoped the patients who took its immunotherapy would experience symptom relief and require less rescue medic...